Trials / Active Not Recruiting

Active Not RecruitingNCT04803058

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation

Status: Active Not Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 18 (estimated)

Sponsor: ITB-Med LLC · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients

Conditions

Kidney Transplantation

Interventions

Type	Name	Description
BIOLOGICAL	TCD601	Investigational Product

Timeline

Start date: 2022-12-14
Primary completion: 2027-03-01
Completion: 2030-03-01
First posted: 2021-03-17
Last updated: 2026-02-06

Locations

3 sites across 2 countries: United States, South Korea

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04803058. Inclusion in this directory is not an endorsement.